Get started
Work

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

Year: 2018
Type: article
Study design: Observational Study
Abstract: Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.
DOI: 10.1038/s41523-018-0057-7
Authors: Lauren M. Moore, Rachel Wilkinson, Mehmet Altan, Maria Toki, Daniel E. Carvajal-Hausdorf, John McGuire, Barbara E. Ehrlich, David L. Rimm
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $3,790
Funders: Breast Cancer Research Foundation, Yale University, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences
OpenAlex ID: W2792941486
FWCI: 0.453
Cites: 10
Cited by: 8
Related to: 10